Cardiovascular System Disease

Categories: Blood diseases, Cardiovascular diseases, Immune diseases

Aliases & Classifications for Cardiovascular System Disease

MalaCards integrated aliases for Cardiovascular System Disease:

Name: Cardiovascular System Disease 12 15
Disease of Subdivision of Hemolymphoid System 12
Abnormality of the Cardiovascular System 29
Disorder of Cardiovascular System 29
Cardiovascular Diseases 43
Cardiovascular Disease 17


External Ids:

Disease Ontology 12 DOID:1287
ICD9CM 34 429.2
MeSH 43 D002318
NCIt 49 C2931
SNOMED-CT 67 49601007
ICD10 32 I51.6
UMLS 71 C0007222

Summaries for Cardiovascular System Disease

Disease Ontology : 12 A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis.

MalaCards based summary : Cardiovascular System Disease, also known as disease of subdivision of hemolymphoid system, is related to coronary heart disease 1 and vascular disease. An important gene associated with Cardiovascular System Disease is MIR210 (MicroRNA 210), and among its related pathways/superpathways are Adipogenesis and Folate Metabolism. The drugs Dimethyl fumarate and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and kidney, and related phenotypes are cardiovascular system and liver/biliary system

Wikipedia : 74 Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. CVD... more...

Related Diseases for Cardiovascular System Disease

Diseases in the Cardiovascular System Disease family:

Autoimmune Disease of Cardiovascular System

Diseases related to Cardiovascular System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1276)
# Related Disease Score Top Affiliating Genes
1 coronary heart disease 1 34.4 SERPINE1 NOS3 MIR145 INS IL6 EDN1
2 vascular disease 34.1 SERPINE1 REN NOS3 MIR145 MIR143 INS
3 familial hypercholesterolemia 34.1 NOS3 INS IL6 CRP APOB APOA1
4 non-alcoholic fatty liver disease 33.9 SERPINE1 INS IL6 CRP APOB APOA1
5 heart valve disease 33.7 REN EDN1 CRP ALB ACE
6 tangier disease 33.6 APOB APOA1 ALB
7 abdominal obesity-metabolic syndrome 1 33.6 SERPINE1 NOS3 INS APOB ADIPOQ
8 hyperthyroidism 33.5 REN INS CRP ALB
9 hyperlipidemia, familial combined, 3 33.5 INS APOB APOA1 ADIPOQ
10 arteriolosclerosis 33.4 REN ALB ADIPOQ
11 lipid metabolism disorder 33.3 SERPINE1 INS IL6 CRP APOB APOA1
12 chronic kidney disease 33.3 SERPINE1 REN NOS3 INS IL6 EDN1
13 pericardium disease 33.2 REN IL6 CRP ALB ACE
14 heart conduction disease 33.2 REN INS CRP ALB ACE
15 kidney disease 33.2 SERPINE1 REN NOS3 INS IL6 EDN1
16 atherosclerosis susceptibility 33.2 SERPINE1 NOS3 INS IL6 EDN1 CRP
17 prediabetes syndrome 33.1 INS IL6 CRP APOB ALB ADIPOQ
18 peripheral vascular disease 33.1 SERPINE1 NOS3 INS IL6 CRP APOB
19 cerebrovascular disease 33.1 SERPINE1 REN INS IL6 CRP APOB
20 hypercholesterolemia, familial, 1 33.1 NOS3 INS CRP APOB APOA1 ACE
21 congestive heart failure 33.1 REN NOS3 INS IL6 EDN1 CRP
22 myocardial infarction 33.1 SERPINE1 REN NOS3 MIR210 INS IL6
23 hypertension, essential 33.0 SERPINE1 REN NOS3 MIR210 MIR143 INS
24 body mass index quantitative trait locus 11 33.0 SERPINE1 REN NOS3 MIR143 INS IL6
25 sleep apnea 32.9 REN NOS3 INS IL6 EDN1 CRP
26 heart disease 32.8 SERPINE1 REN NOS3 MIR210 INS IL6
27 pre-eclampsia 32.8 SERPINE1 REN NOS3 MIR210 INS IL6
28 angina pectoris 32.8 NOS3 INS IL6 EDN1 CRP APOA1
29 end stage renal failure 32.8 REN IL6 CRP APOB ALB ADIPOQ
30 peripheral artery disease 32.8 NOS3 IL6 EDN1 CRP CDKN2B-AS1 APOB
31 hyperglycemia 32.8 SERPINE1 NOS3 INS IL6 APOB ALB
32 diabetes mellitus, noninsulin-dependent 32.7 SERPINE1 REN NOS3 INS IL6 EDN1
33 intermediate coronary syndrome 32.7 REN INS IL6 CRP APOB APOA1
34 fatty liver disease 32.6 INS IL6 CRP APOB ALB ADIPOQ
35 arteries, anomalies of 32.6 SERPINE1 REN NOS3 MIR210 MIR145 MIR143
36 pulmonary hypertension 32.6 SERPINE1 REN NOS3 IL6 EDN1 CRP
37 coronary artery anomaly 32.6 SERPINE1 NOS3 MIR145 IL6 EDN1 CRP
38 osteoporosis 32.6 SERPINE1 NOS3 INS IL6 EDN1 CRP
39 hypertriglyceridemia, familial 32.6 SERPINE1 INS APOB APOA1
40 systemic lupus erythematosus 32.6 SERPINE1 NOS3 MIR210 INS IL6 CRP
41 stroke, ischemic 32.6 SERPINE1 REN NOS3 IL6 CRP CDKN2B-AS1
42 impotence 32.5 NOS3 INS EDN1 ACE
43 aortic aneurysm 32.5 MIR145 IL6 HIF1A-AS1 CRP CDKN2B-AS1 ACE
44 hypothyroidism 32.5 SERPINE1 REN INS CRP APOB APOA1
45 microvascular complications of diabetes 3 32.4 REN MIR217 INS ALB ACE
46 pulmonary disease, chronic obstructive 32.4 INS IL6 CRP ALB ACE
47 acute myocardial infarction 32.4 SERPINE1 REN INS IL6 EDN1 CRP
48 hyperuricemia 32.4 REN INS CRP APOB ALB
49 migraine with or without aura 1 32.3 NOS3 INS IL6 EDN1 CRP ALB
50 proteasome-associated autoinflammatory syndrome 1 32.3 INS IL6 CRP ALB ADIPOQ

Graphical network of the top 20 diseases related to Cardiovascular System Disease:

Diseases related to Cardiovascular System Disease

Symptoms & Phenotypes for Cardiovascular System Disease

MGI Mouse Phenotypes related to Cardiovascular System Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 ACE ADIPOQ ALB APOA1 APOB CRP
2 liver/biliary system MP:0005370 9.81 ACE ADIPOQ ALB APOA1 APOB IL6
3 muscle MP:0005369 9.56 ADIPOQ ALB APOB EDN1 IL6 INS
4 renal/urinary system MP:0005367 9.28 ACE ADIPOQ ALB EDN1 IL6 INS

Drugs & Therapeutics for Cardiovascular System Disease

Drugs for Cardiovascular System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
Tranexamic Acid Approved Phase 4 1197-18-8 5526
Norethindrone Approved Phase 4 68-22-4 6230
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
Pantoprazole Approved Phase 4 102625-70-7 4679
Methimazole Approved Phase 4 60-56-0 1349907
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
9 Tomato Approved Phase 4
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
Nicotine Approved Phase 4 54-11-5 942 89594
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
Tipranavir Approved, Investigational Phase 4 174484-41-4 65027
Nevirapine Approved Phase 4 129618-40-2 4463
Didanosine Approved Phase 4 69655-05-6 50599
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
Indinavir Approved Phase 4 150378-17-9 5362440
Dipyridamole Approved Phase 4 58-32-2 3108
Ustekinumab Approved, Investigational Phase 4 815610-63-0
Ziprasidone Approved Phase 4 146939-27-7 60854
Altretamine Approved Phase 4 645-05-6 2123
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
Doxazosin Approved Phase 4 74191-85-8 3157
Vancomycin Approved Phase 4 1404-90-6 441141 14969
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
Colchicine Approved Phase 4 64-86-8 6167 2833
Insulin glargine Approved Phase 4 160337-95-1
Insulin detemir Approved Phase 4 169148-63-4 5311023
Rilonacept Approved, Investigational Phase 4 501081-76-1 104924
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
Travoprost Approved Phase 4 157283-68-6 5282226
Sevelamer Approved Phase 4 52757-95-6
Drospirenone Approved Phase 4 67392-87-4 68873
Tolvaptan Approved Phase 4 150683-30-0 216237
Ibuprofen Approved Phase 4 15687-27-1 3672
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537

Interventional clinical trials:

(show top 50) (show all 8307)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
2 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
3 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) Unknown status NCT00217178 Phase 4 Vitamins: Folic acid, B6, B12
4 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
5 HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study) Unknown status NCT00106886 Phase 4 Folic acid, vitamin B6 and B12 or placebo
6 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
7 Does Administration of Vitamin D in African Americans With Hypovitaminosis D and Type 2 DM Improve Inflammatory Markers of Cardiovascular Disease? Unknown status NCT01153243 Phase 4 Ergocalciferol;Placebo pill
8 Does Rosuvastatin Delay Progression of Atherosclerosis in People With HIV Infection at Moderate Cardiovascular Risk? A Multicentre Randomized, Double Blind Placebo-controlled Trial Unknown status NCT01813357 Phase 4 Rosuvastatin
9 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
10 Levosimendan Versus Dobutamine in Cardiopatic Patients Undergoing Major Non Cardiac Surgery Unknown status NCT02012946 Phase 4 Levosimendan;Dobutamine
11 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
12 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
13 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
14 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Unknown status NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
15 Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease Unknown status NCT01893996 Phase 4 Adalimumab;Placebo
16 Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes Unknown status NCT01240070 Phase 4
17 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
18 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
19 Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
20 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
21 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
23 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
24 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
25 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
26 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
27 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
28 The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus Unknown status NCT02418884 Phase 4 rosuvastatin
29 Effects of Intensive Antihypertensive Therapies on the Risk of Stroke in Hypertensive Adults: A Prospective Randomized Open-Label Blinded-Endpoint Trial, a Feasibility Study Unknown status NCT02817503 Phase 4 Standard BP control;Moderate BP control;Intensive BP control
30 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
31 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
32 Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
33 Efficacy and Safety of Ivabradine in Hemodialysed Patients With Increased Heart Rate Unknown status NCT01364077 Phase 4 Ivabradine;Placebo
34 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
35 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
36 Hemostasis Pad Using Chitosan After Invasive Percutaneous Procedures Unknown status NCT02954029 Phase 4
37 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
38 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
39 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Unknown status NCT00879060 Phase 4 spironolactone
40 Randomized Clinical Study to Assess the Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias Unknown status NCT01717469 Phase 4
41 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
42 Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
43 Treatment of HYpertension: Morning Versus Evening Unknown status NCT02214498 Phase 4 Enalapril/hydrochlorothiazide;Placebo
44 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
45 Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
46 Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
47 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
48 Evaluate Efficacy and Safety of Extended Adjuvant Treatment With Letrozole in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Have Completed 5 Years of Toremifene Unknown status NCT01072318 Phase 4 Letrozole
49 Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
50 Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin

Search NIH Clinical Center for Cardiovascular System Disease

Cochrane evidence based reviews: cardiovascular diseases

Genetic Tests for Cardiovascular System Disease

Genetic tests related to Cardiovascular System Disease:

# Genetic test Affiliating Genes
1 Disorder of Cardiovascular System 29 ACE
2 Abnormality of the Cardiovascular System 29

Anatomical Context for Cardiovascular System Disease

MalaCards organs/tissues related to Cardiovascular System Disease:

Heart, Endothelial, Kidney, Testes, Bone, Liver, Breast

Publications for Cardiovascular System Disease

Articles related to Cardiovascular System Disease:

(show top 50) (show all 2957)
# Title Authors PMID Year
Intracellular delivery strategies for microRNAs and potential therapies for human cardiovascular diseases. 46
21045204 2010
MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. 46
20624982 2010
MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. 46
19786632 2009
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. 46
19578358 2009
MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. 46
18417479 2008
Citric acid-enhanced dissolution of polyphenols during soaking of different teas. 61
31506961 2019
A novel antioxidant Mito-Tempol inhibits ox-LDL-induced foam cell formation through restoration of autophagy flux. 61
30321700 2018
Screening key genes for abdominal aortic aneurysm based on gene expression omnibus dataset. 61
29439675 2018
Circular RNA WDR77 target FGF-2 to regulate vascular smooth muscle cells proliferation and migration by sponging miR-124. 61
29042195 2017
[Nursing care in elderly patients with cardiovascular disease]. 61
28976398 2017
Multi-scale Modeling of the Cardiovascular System: Disease Development, Progression, and Clinical Intervention. 61
27138523 2016
Farnesoid-X-receptor expression in monocrotaline-induced pulmonary arterial hypertension and right heart failure. 61
26392308 2015
[Hyperprolactinaemia and bone mineral density]. 61
26319389 2015
Elderly deaths in Ankara, Turkey. 61
24962235 2014
Association of adrenergic receptor gene polymorphisms in gallbladder cancer susceptibility in a North Indian population. 61
24556804 2014
Denervation of nerve terminals in renal arteries: one-year follow-up of interventional treatment of arterial hypertension. 61
24408071 2014
[Retrospective analysis of 190 cases of hospitalized patients with psoriasis]. 61
24384952 2013
[Biomarkers and risk factors of cardiovascular system disease in diabetes mellitus type 2]. 61
23951913 2013
Atrial natriuretic peptide and oxidative stress. 54
20385186 2010
No or only population-specific effect of PON1 on human longevity: a comprehensive meta-analysis. 54
20362697 2010
Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. 54
20385972 2010
Dalcetrapib: a review of Phase II data. 54
20465364 2010
Adenoviral-mediated overexpression of DDAH improves vascular tone regulation. 54
20219849 2010
Neuropeptide Y and sleep. 54
20122859 2010
Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. 54
20515790 2010
Regulatory polymorphism in transcription factor KLF5 at the MEF2 element alters the response to angiotensin II and is associated with human hypertension. 54
20086047 2010
Residential traffic exposure, pulse pressure, and C-reactive protein: consistency and contrast among exposure characterization methods. 54
20123638 2010
Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase. 54
20205608 2010
Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease. 54
20096841 2010
ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. 54
20189274 2010
Changes in the immune system during menopause and aging. 54
20515802 2010
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. 54
20415560 2010
Hormonal modulation of endothelial NO production. 54
20213497 2010
Gene therapy to improve high-density lipoprotein metabolism and function. 54
20196736 2010
N-terminal ProBNP distribution and correlations with biological characteristics in apparently healthy Greek population: ATTICA study. 54
19815605 2010
High mobility group box-1 and cardiovascular diseases. 54
20464035 2010
Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection. 54
20297868 2010
Pro-atherothrombotic effects of leptin in human coronary endothelial cells. 54
20174754 2010
Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. 54
20008829 2010
The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? 54
20124546 2010
A significant decline in IGF-I may predispose young Africans to subsequent cardiometabolic vulnerability. 54
20215395 2010
ROCK2 associates with lectin-like oxidized LDL receptor-1 and mediates oxidized LDL-induced IL-8 production. 54
20181930 2010
Association of serum lipoprotein ratios with insulin resistance in type 2 diabetes mellitus. 54
20516535 2010
Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-kappaB. 54
20458445 2010
Higher leptin levels in Asian Indians than Creoles and Europids: a potential explanation for increased metabolic risk. 54
20125099 2010
The axis of thrombospondin-1, transforming growth factor beta and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis. 54
19485899 2010
[Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study]. 54
20446588 2010
Association between apoliprotein E gene polymorphism and hypercholesterolemic phenotype in Maracaibo, Zulia state, Venezuela. 54
20019593 2010
Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin. 54
20064494 2010
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. 54
20005515 2010

Variations for Cardiovascular System Disease

Expression for Cardiovascular System Disease

Search GEO for disease gene expression data for Cardiovascular System Disease.

Pathways for Cardiovascular System Disease

GO Terms for Cardiovascular System Disease

Cellular components related to Cardiovascular System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 SERPINE1 REN INS IL6 EDN1 CRP
2 endoplasmic reticulum lumen GO:0005788 9.55 INS IL6 APOB APOA1 ALB
3 extracellular space GO:0005615 9.47 SERPINE1 REN MIR210 MIR143 MIR10A INS
4 intermediate-density lipoprotein particle GO:0034363 9.26 APOB APOA1

Biological processes related to Cardiovascular System Disease according to GeneCards Suite gene sharing: